UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 13, 2011 (January
13, 2011)
BioDrain
Medical, Inc.
(Exact
name of Registrant as Specified in its Charter)
Minnesota
(State or
Other Jurisdiction of Incorporation)
|
333-155299
|
33-1007393
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
2060
Centre Pointe Boulevard, Suite 7
Mendota
Heights, Minnesota 55120
(Address
of Principal Executive Offices and Zip Code)
(651)
389-4800 (651)
389-4800
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
(b)
|
Departure
of Officer or Director
|
Effective
January 13, 2011, James E. Dauwalter resigned as a member of the Registrant’s
Board of Directors for personal reasons. Mr. Dauwalter has no
disagreement with management or other directors of the Registrant and is
supportive of its plans for growth.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
January 13, 2011
|
BIODRAIN
MEDICAL, INC.
|
|||
|
By:
|
/s/ Kevin
R. Davidson
|
||
|
Kevin
R. Davidson
|
|||
|
Chief
Executive Officer,
|
|||